Morgan Stanley Has Lowered Expectations for Stevanato Group (NYSE:STVN) Stock Price

Stevanato Group (NYSE:STVN) had its price objective decreased by analysts at Morgan Stanley from $24.00 to $19.00 in a research report issued on Friday,Benzinga reports. The firm currently has an “equal weight” rating on the stock.

A number of other analysts also recently issued reports on STVN. Jefferies Financial Group set a $17.50 price target on Stevanato Group in a report on Tuesday, February 10th. Wall Street Zen lowered shares of Stevanato Group from a “buy” rating to a “hold” rating in a research note on Saturday, February 14th. KeyCorp cut their price target on Stevanato Group from $37.00 to $32.00 and set an “overweight” rating for the company in a research note on Thursday. Weiss Ratings restated a “hold (c)” rating on shares of Stevanato Group in a research report on Monday, December 29th. Finally, Citigroup reduced their target price on Stevanato Group from $32.00 to $26.00 and set a “buy” rating for the company in a report on Thursday. One investment analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy”.

Stevanato Group Stock Down 4.8%

Shares of STVN traded down €0.76 during mid-day trading on Friday, hitting €15.15. 104,423 shares of the company’s stock were exchanged, compared to its average volume of 737,959. Stevanato Group has a fifty-two week low of €13.91 and a fifty-two week high of €28.00. The stock’s 50-day moving average is €17.69 and its 200-day moving average is €21.71. The company has a debt-to-equity ratio of 0.26, a quick ratio of 1.30 and a current ratio of 1.89. The company has a market cap of $4.59 billion, a price-to-earnings ratio of 26.12, a P/E/G ratio of 1.44 and a beta of 0.57.

Institutional Investors Weigh In On Stevanato Group

A number of hedge funds and other institutional investors have recently made changes to their positions in STVN. Ranger Investment Management L.P. increased its holdings in shares of Stevanato Group by 125.6% during the 2nd quarter. Ranger Investment Management L.P. now owns 1,321,030 shares of the company’s stock valued at $32,273,000 after acquiring an additional 735,417 shares during the last quarter. Loomis Sayles & Co. L P acquired a new stake in Stevanato Group in the 2nd quarter worth $13,729,000. Champlain Investment Partners LLC grew its position in Stevanato Group by 68.7% during the second quarter. Champlain Investment Partners LLC now owns 1,300,799 shares of the company’s stock worth $31,779,000 after buying an additional 529,950 shares in the last quarter. Fideuram Intesa Sanpaolo Private Banking S.P.A. acquired a new stake in shares of Stevanato Group during the 4th quarter worth approximately $9,269,000. Finally, Artisan Partners Limited Partnership increased its holdings in Stevanato Group by 20.0% in the 2nd quarter. Artisan Partners Limited Partnership now owns 2,733,782 shares of the company’s stock valued at $66,786,000 after buying an additional 455,323 shares during the period.

Stevanato Group News Summary

Here are the key news stories impacting Stevanato Group this week:

• Positive Sentiment: Reported Q4 results beat expectations (EPS ~€0.21 vs. €0.20) with FY25 revenue +7% (9% at constant currency) and record sales from High‑Value Solutions; management set a 2026 revenue target up to €1.308B with HVS expected to reach ~48% of sales — supports the long‑term growth story. Read More.
• Positive Sentiment: Management reiterated that most capex (~90%) is being directed to HVS (High‑Value Solutions) expansion, which should drive future margin mix improvement and supports buy‑and‑hold theses that emphasize recurring pharma demand. Read More.
• Neutral Sentiment: Earnings call and transcripts provide detail on drivers and near‑term execution; the beat was modest and commentary suggests some margin pressure remains, so investors get clarity but no radical upside surprise. Read More. | Read More.
• Negative Sentiment: Several sell‑side desks trimmed price targets (Citigroup cut PT from $32 to $26 but stayed Buy; KeyCorp/KeyBanc cut from $37 to $32 and kept Overweight). Lower PTs reduce near‑term analyst‑driven upside and can pressure the stock after recent gains. Read More. | Read More.
• Negative Sentiment: The shares had rebounded sharply after the Q4 beat (reports of a ~17% surge), so some of today’s weakness looks like profit‑taking and repositioning; volume is well below average, which can amplify moves. Read More.

Stevanato Group Company Profile

Stevanato Group is a global provider of primary packaging solutions and related services for the pharmaceutical and biotech industries. The company specializes in the design, development and manufacturing of glass drug containers such as vials, cartridges and pre-fillable syringes, as well as advanced inspection systems and assembly equipment. Its integrated offerings cover the entire packaging supply chain, from component production to bespoke filling lines and serialization technology.

In addition to its core glass business, Stevanato Group delivers engineering services and process validation support to pharmaceutical customers.